Evidence map›Paper›PMID 30903344›Full record

ArticleInvestigational new drugs2019

Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.

Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida, Kenji Yamao, Hisato Igarashi, Chigusa Morizane, Shunsuke Kondo, Nobumasa Mizuno, Kazuo Hara, Akira Sawaki and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Tetsuhide ItoDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, Japan. itopapa@intmed3.med.kyushu-u.ac.jp.
Takuji OkusakaHepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Toshirou NishidaDepartment of Surgery, Osaka Police Hospital, Osaka, Japan.
Kenji YamaoDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
Hisato IgarashiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, Japan.
Chigusa MorizaneHepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Shunsuke KondoHepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Nobumasa MizunoDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
Kazuo HaraDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
Akira SawakiDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
Satoshi HashigakiPfizer Japan Inc., Tokyo, Japan.
Nobuyuki KimuraPfizer Japan Inc., Tokyo, Japan.
Mami MurakamiPfizer Japan Inc., Tokyo, Japan.
Emiko OhkiPfizer Japan Inc., Tokyo, Japan.
Richard C ChaoPfizer Oncology, La Jolla, CA, USA.
Masayuki ImamuraKansai Electric Power Company Hospital, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the original publication of this article, the license subtype should be CC BY and not CC BY-NC.

Identifiers

PMID30903344
PMCPMC6828105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.